Late Breaking Abstract - Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma
G. Van Hulst (Liège , Belgium), J. Jorssen (Liège, Belgium), N. Jacobs (Liège, Belgium), M. Henket (Liège, Belgium), R. Louis (Liège, Belgium), F. Schleich (Liège, Belgium), F. Bureau (Liège, Belgium), C. Desmet (Liège, Belgium)
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Session: Asthma clinical trials and real-life studies
Session type: E-poster
Number: 890
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Van Hulst (Liège , Belgium), J. Jorssen (Liège, Belgium), N. Jacobs (Liège, Belgium), M. Henket (Liège, Belgium), R. Louis (Liège, Belgium), F. Schleich (Liège, Belgium), F. Bureau (Liège, Belgium), C. Desmet (Liège, Belgium). Late Breaking Abstract - Anti-IL-5 mepolizumab minimally influences residual blood eosinophils in severe asthma. 890
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: